How Peptides Are Made: Solid-Phase Peptide Synthesis Explained

Research Use Only. This article is written for laboratory and research professionals. The
compounds discussed are supplied strictly for in-vitro laboratory research. They are not drugs,
dietary supplements, or foods. They are not for human or veterinary use, and not for diagnostic
or therapeutic use. Nothing here is medical, legal, or regulatory advice.

The short answer. Peptides are made by joining amino acids one at a time, while the growing chain stays anchored to a solid plastic bead. That is solid-phase peptide synthesis. Each cycle strips a protecting group, adds an activated amino acid, and washes the excess away. The finished chain is cleaved off, purified and freeze-dried.

Why you cannot just mix amino acids together

A peptide bond is an amide: one amino acid's carboxyl condenses with the next one's amino group, releasing water. A flask of mixed amino acids will not make one, for two reasons.

Specificity. Every amino acid has an amine at one end and a carboxylic acid at the other, and about half carry a reactive side chain as well. Mix them and they react in every direction. The result is a soup of every possible sequence, your target an unrecoverable trace inside it. (See what are peptides for the underlying chemistry, and types of peptides for how the finished products get classified.)

Thermodynamics. Joining a free acid to a free amine in water is uphill. The two trade a proton and sit as an unreactive ammonium carboxylate, because hydroxide is a poor leaving group.

Both have one answer: block every reactive group you are not using with a removable protecting group, and activate the carboxyl you want to react.

Merrifield and the invention of SPPS

Before 1963, peptides were built in solution, with every intermediate isolated and purified before the next coupling. Solution phase peptide synthesis survives for short sequences and fragment joining, but each purification loses material. A ten-residue chain was a doctoral project.

In 1963 Robert Bruce Merrifield, at the Rockefeller Institute in New York, attached the first amino acid covalently to a bead of cross-linked polystyrene and grew the peptide there, still tethered. Purification becomes a plumbing problem: product stuck to a bead, excess reagent in solution, separated by rinsing. You can then drive every coupling to completion with a large excess of reagent, because the excess costs only solvent. His paper reported the tetrapeptide Leu-Ala-Gly-Val.

Because every cycle is identical, the process could be mechanised. By 1969 the laboratory had built ribonuclease A, a catalytically active 124-residue enzyme, through several hundred consecutive chemical operations. Merrifield received the 1984 Nobel Prize in Chemistry, alone, for his development of methodology for chemical synthesis on a solid matrix.

The SPPS cycle, step by step

Solid-phase peptide synthesis (SPPS) is a loop: one turn adds one residue.

1. Resin loading. The C-terminal amino acid is tied to the resin through a connector called a linker, temporarily protected at its alpha-amino group and permanently on any reactive side chain.
2. Deprotection. The temporary group is stripped off, exposing the free amine.
3. Wash. The resin is rinsed with DMF; leftover reagent would spoil the coupling.
4. Coupling. The next amino acid arrives protected and activated at its carboxyl; the free amine attacks it and a peptide bond forms. Reagents run in three- to fivefold excess.
5. Wash. Excess reagent and by-products are rinsed away.
6. Repeat from step 2.
7. Cleavage. Strong acid severs the linker and strips side-chain protection, releasing the peptide.

A synthesiser runs this in fifteen minutes to two hours per residue. Completeness is checked by the ninhydrin (Kaiser) test, which turns blue when unreacted amines remain.

Why synthesis runs backwards

Ribosomes build proteins N-terminus to C-terminus. SPPS runs the other way because the C-terminal residue is bolted to the resin, leaving the amino end free to extend.

The chemical reason is better. Each coupling activates a single protected amino acid, never the growing chain. Activate a peptide's C-terminal carboxyl and it cyclises to an oxazolone, scrambling that residue's stereochemistry. Sequences are still written N-terminus to C-terminus, per IUPAC-IUB nomenclature for amino acids and peptides, the reverse of assembly order.

Fmoc versus Boc

Boc (tert-butyloxycarbonyl) is acid-labile and comes off with 25 to 50 percent trifluoroacetic acid. Side chains carry benzyl-type protection, stripped at the end with anhydrous hydrogen fluoride. HF is the obstacle: severely corrosive, it attacks glass and needs dedicated fluoropolymer apparatus.

Fmoc (9-fluorenylmethoxycarbonyl), introduced by Carpino and Han in 1970, is base-labile and comes off with about 20 percent piperidine in DMF. The mechanism is an elimination: piperidine removes the acidic proton at carbon-9 of the fluorene, the ring aromatises, carbon dioxide leaves, and the dibenzofulvene released is trapped by a second piperidine. Side-chain protection is acid-labile, removed by TFA. No HF anywhere.

Fmoc/tBu is orthogonal, and the word is precise: base takes the temporary group and cannot touch the permanent ones, acid the reverse. Boc/benzyl is not, because both come off with acid and differ only in how much is needed, so each of the dozens of TFA treatments nibbles at the linker and side-chain protection. That is much of why Fmoc dominates synthetic peptide synthesis.

Resins and linkers

The support is usually polystyrene cross-linked with about 1 percent divinylbenzene, or a polyethylene glycol hybrid; the bead is inert. The chemistry lives in the linker bridging bead and peptide, which sets how much acid releases the peptide and what group the C-terminus carries.

• Wang resin (a p-alkoxybenzyl alcohol linker) gives a free C-terminal carboxylic acid under concentrated TFA. The Fmoc workhorse.
• Rink amide resin gives a C-terminal carboxamide instead. Many natural peptides are C-terminally amidated, so this is routine.
• 2-chlorotrityl chloride resin releases the peptide under very dilute acid with side-chain protection intact, which suits protected fragments, and suppresses racemisation on loading.

Coupling reagents, and why activation is needed

A free carboxylate will not react with an amine, so the coupling reagent swaps that terrible hydroxide leaving group for a good one. Peptide bond formation then follows nucleophilic acyl substitution: the amine nitrogen's lone pair attacks the carbonyl carbon, a tetrahedral intermediate forms, and it collapses by expelling the leaving group.

Carbodiimides came first. DIC and DCC add across the acid to give a reactive O-acylisourea; DIC is preferred on solid phase because its urea by-product dissolves in DMF, whereas DCC's precipitates among the beads. Uronium and aminium salts such as HBTU and HATU are faster and cleaner, which is why automated instruments run on them. They need a base such as DIPEA to deprotonate the acid first.

The bare O-acylisourea is unstable. Its worst habit is cyclising to a five-membered oxazolone, where the alpha proton turns acidic enough for base to pull off. Replace that proton and the stereocentre can invert, leaving a D-residue inside an L-peptide. Additives solve this: HOBt, HOAt and Oxyma convert the O-acylisourea into a more stable active ester, reactive enough to couple efficiently but far less prone to racemisation.

Where peptide synthesis goes wrong

Every step is above 95 percent efficient, none is 100 percent, and over a long sequence the gap compounds.

Deletion sequences. If a coupling stalls at 99 percent, one chain in a hundred keeps a free amine. The next cycle extends it as though nothing had happened, and it ends up missing one internal residue. Those are the hardest impurities to remove, since a peptide short by one residue behaves almost identically on a column. Hence capping: acetic anhydride acetylates the failed amines, turning an inseparable deletion into an easily resolved truncated fragment.

Aggregation and difficult sequences. Past roughly the fifth to fifteenth residue, chains rich in beta-branched or hydrophobic residues hydrogen-bond into beta-sheets inside the bead. Reagents can no longer reach them, and both coupling and deprotection slow to a crawl. Fixes include pseudoproline dipeptides that kink the backbone, backbone amide protection, lower resin loading, PEG supports and heat. The standard reference, Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences, treats aggregation as the central obstacle.

Aspartimide formation. Under repeated piperidine treatment, the backbone nitrogen after an aspartate attacks its side-chain ester and closes a succinimide ring, which reopens to either the normal alpha-linked peptide or a beta-linked isomer, and can epimerise. Asp-Gly is the worst case.

The arithmetic. Cumulative yield is per-step efficiency raised to the number of steps.

Per-step efficiency	10 steps	30 steps	50 steps
99.5%	95%	86%	78%
99%	90%	74%	61%
98%	82%	55%	36%
95%	60%	21%	8%

Ninety-nine percent per step sounds excellent, yet over thirty steps it returns about 74 percent, and the missing quarter sits in the crude as closely related impurities. At 95 percent per step a 30-mer returns 21 percent. Hence a 10-mer and a 40-mer differ in price by far more than fourfold.

Cleavage and final deprotection

In Fmoc synthesis, cleavage from the resin and side-chain deprotection happen together, usually in 90 to 95 percent TFA.

The reaction throws off a swarm of carbocations as the tert-butyl, trityl and Pbf groups leave. They are electrophiles, and they find the electron-rich side chains of tryptophan, tyrosine, methionine and cysteine. Left alone, they alkylate the peptide. Hence sacrificial scavengers: a few percent each of water and triisopropylsilane, plus a thiol such as 1,2-ethanedithiol for cysteine-containing sequences.

The crude peptide is recovered by ether precipitation into cold diethyl ether: the polar peptide is insoluble and drops out as a solid while scavengers, protecting groups and most of the TFA stay dissolved.

Purification by reverse-phase HPLC

Crude peptide is not product. It is separated by preparative reverse-phase HPLC on silica bearing C18 (octadecyl) chains, the default because peptides are amphipathic and a long alkyl chain resolves species differing by a single residue.

The mobile phase is water and acetonitrile with about 0.1 percent TFA. The TFA acidifies, but it also ion-pairs, neutralising the positive charges on lysine, arginine and the N-terminus and sharpening the peaks. Separation uses gradient elution, because peptides behave in near on-off fashion: below a threshold organic concentration a peptide stays glued to the column, and a fraction of a percent above it the band desorbs at once.

What "purity by HPLC at 214 nm" means

Detection sits at 214 nm because that is where the peptide bond itself absorbs. The amide chromophore is strong in the far ultraviolet, and 214 nm is the practical compromise between that signal and the transparency of acetonitrile and TFA. The alternative, 280 nm, sees only tryptophan and tyrosine, so a peptide with neither is invisible.

Purity is then an area percentage: main peak area over total peak area. Two limits follow. It is relative, and only among UV-absorbing species, so it misses salts, water and counterion. And it cannot see a co-eluting impurity. So the chromatogram matters more than the number, and it is worth asking for the analytical package for your specific lot when reviewing any research peptide catalogue.

Lyophilization: why peptides arrive as a powder

Pooled HPLC fractions are a dilute solution of peptide in water, acetonitrile and TFA. Water is the medium in which peptides degrade, through hydrolysis, deamidation and oxidation.

Lyophilization, or freeze-drying, removes it. The solution is frozen solid and placed under deep vacuum. Ice sublimes straight to vapour without ever becoming liquid, and a warmer secondary drying step desorbs the bound water. Because the solid never melts, what remains is a porous replica of the ice crystals: the light, fluffy cake in the vial.

One detail surprises people: lyophilized peptides are not pure peptide by mass. TFA from cleavage and from the mobile phase forms salts with every basic group: lysine and arginine side chains, histidine, and the N-terminal amine. That counterion can be 5 to 20 percent of the vial's mass, plus a few percent residual water, so a peptide reported as 98 percent pure by HPLC may be 80 percent peptide by weight. Both figures are correct.

Analytical confirmation

Purity says how much of one thing is present, not what it is.

Mass spectrometry is the identity test. ESI-MS gives multiply charged ions that deconvolute to one molecular mass; MALDI-TOF gives mainly singly charged ions and tolerates salt better, which suits larger peptides. You compare the measured mass with the one calculated from the sequence. A match is strong evidence, not proof: leucine and isoleucine are identical in mass, and any rearrangement gives the same total.

Amino acid analysis complements it: the peptide is hydrolysed in strong acid and the liberated amino acids quantified chromatographically. Because it measures amino acid mass, it gives the peptide content, the fraction of the vial that is genuinely peptide. Our guide to reading a peptide certificate of analysis covers what each field claims.

Recombinant and enzymatic routes

Past a certain length, chemistry stops being the sensible route. In recombinant expression, a gene encoding the sequence goes into a host such as E. coli or the yeast Pichia, and the host's ribosomes build the chain. Biology manages far higher per-bond fidelity than chemical coupling, and yield does not decay exponentially with length. The trade-off is flexibility: only the twenty proteinogenic amino acids, with no D-residues or non-natural modifications.

The crossover sits roughly between 30 and 50 residues. Below it, SPPS is faster and cheaper; above it, yield loss and purification burden climb steeply. Chemistry has pushed that boundary upward. Native chemical ligation joins two fragments through a C-terminal thioester and an N-terminal cysteine, which puts chains over 100 residues within reach. Enzymatic ligation, using transpeptidases such as sortase A, joins fragments without protecting groups.

Research grade versus GMP peptide synthesis

The same sequence can be made to wildly different standards. This is the most misunderstood distinction in peptide supply, and it is not a purity difference: a research-grade and a GMP peptide can be chemically identical at the same HPLC purity.

What differs is the system around the chemistry. GMP manufacture of an active pharmaceutical ingredient is defined by ICH Q7, adopted by FDA as good manufacturing practice guidance for active pharmaceutical ingredients: a quality unit independent of production, qualified facilities and equipment, validated analytical methods, qualified suppliers, complete batch records, change control, retained samples, a stability programme, and traceability to the finished lot.

Research grade means the material was made and characterised competently and comes with a certificate of analysis. It means none of the above, and the price gap reflects that infrastructure, not better chemistry. Grade adjectives implying a clinical standard have no regulatory definition for research chemicals: a grade describes documentation, never permitted use.

Custom peptide synthesis

Custom peptide synthesis means a sequence assembled to order rather than taken from stock, and everything above sets its feasibility, timeline and cost: chain length, difficult residues, aggregation risk, C-terminal functionality, modifications, purity and scale. A well-behaved 8-mer at 95 percent purity is routine; a 45-mer with two cysteines, an Asp-Gly motif and a hydrophobic core at 98 percent is not.

Compliance notice. Nothing in this article should be read as guidance for administering any
compound to a human or animal subject. "Research Use Only" describes the conditions under which
a material is supplied; it is not a determination of legal status and confers no exemption from
the Federal Food, Drug, and Cosmetic Act. Researchers are responsible for compliance with all
applicable federal, state, and institutional requirements, and for obtaining any approvals their
work requires.

Frequently asked questions

How are peptides made?

Most research peptides are made by solid-phase peptide synthesis: the first amino acid is anchored to a resin bead, then deprotection, coupling of an activated amino acid and washing repeat once per residue. The chain is then cleaved, purified and freeze-dried.

What is solid phase peptide synthesis?

It keeps the growing peptide covalently attached to an insoluble polymer support. Because the product is bound to a bead and everything else is in solution, excess reagents are removed by washing rather than chromatography. Merrifield introduced it in 1963.

What is the difference between Fmoc and Boc peptide synthesis?

They differ in how the temporary alpha-amino protecting group comes off. Fmoc is base-labile and removed with piperidine; Boc is acid-labile and needs anhydrous hydrogen fluoride for final deprotection. Fmoc dominates because it is genuinely orthogonal and avoids HF.

Why do longer peptides cost so much more?

Yield compounds multiplicatively. At 99 percent efficiency per step, a 30-step synthesis returns about 74 percent and a 50-step synthesis about 61 percent. The shortfall appears as closely related impurities, including deletions that are hard to remove.

Why are peptides supplied as a lyophilized powder?

Water drives hydrolysis, deamidation and oxidation, so peptides are far more stable as dry solids. Lyophilization freezes the purified solution and removes water by sublimation under vacuum, leaving the porous amorphous cake seen in the vial.

What is the difference between HPLC purity and peptide content?

HPLC purity is the main peak area as a percentage of all UV-absorbing peaks. Peptide content is the fraction of the vial's mass that is actually peptide, the balance being counterion, water and salts. A peptide can be 98 percent pure and 80 percent peptide.

What does GMP peptide synthesis add over research grade?

Not different chemistry. GMP adds a documented quality system: an independent quality unit, qualified facilities, validated methods, controlled raw materials, batch records, change control, retained samples and traceability, as set out in ICH Q7.